Ovid Therapeutics (OVID) Non-Current Deffered Revenue (2020)
Ovid Therapeutics' (OVID) quarterly Non-Current Deffered Revenue came in at $10.2 million in Q4 2020, up 2.36% quarter-over-quarter from $9.9 million in Q3 2020.
Powered by 
Analysis
Ovid Therapeutics (OVID) Non-Current Deffered Revenue (2020) Analysis & Trends
Ovid Therapeutics (OVID) has reported Non-Current Deffered Revenue for 1 consecutive years, with $10.2 million the latest figure, recorded in Q4 2020.
- For the quarter ending Q4 2020, Non-Current Deffered Revenue changed N/A year-over-year to $10.2 million; the trailing twelve-month figure through Dec 2020 stood at $10.2 million (changed N/A YoY), and the FY2020 full-year result was $10.2 million, changed N/A from the prior year.
- Non-Current Deffered Revenue rose to $10.2 million in Q4 2020 per OVID's latest filing, from $9.9 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $10.2 million in Q4 2020 and bottomed at $9.9 million in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | - |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | - |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | - |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | - |